Currently just Rheumatoid Arthritis but seems company plans to extend research possibly to Multiple Sclerosis also.
Hollis-Eden Pharmaceuticals Presents Positive Data with HE3286 in Preclinical Model of Established Rheumatoid Arthritis
Companies mentioned in this article:
2/2/2007 @ 8:02 AM
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH) is presenting new data this week showing that HE3286, an orally bio-available small molecule compound, produced a statistically significant reduction in disease in a rodent model of established arthritis. The data, ...